Gene · 710
Papers4,575
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
881 to 900 of 4,575
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Longitudinal experience with treatment of acquired angioedema using tranexamic acid. | Allergy Asthma Proc | 2022 | 36065111 | PubTator, text mining | PubMed |
| Prioritizing Candidate Genes for Type 2 Diabetes Mellitus using Integrated Network and Pathway Analysis. | Avicenna J Med Biotechnol | 2022 | 36061131 | PubTator, text mining | PubMed |
| Role of endometrial microRNAs in repeated implantation failure (mini-review). | Front Cell Dev Biol | 2022 | 36060804 | PubTator, text mining | PubMed |
| Placental damage in pregnancies with systemic lupus erythematosus: A narrative review. | Front Immunol | 2022 | 36059466 | PubTator, text mining | PubMed |
| [Clinical and genetic studies of a family with hereditary angioedema]. | Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi | 2022 | 36058666 | PubTator, text mining | PubMed |
| Protocol to identify host-viral protein interactions between coagulation-related proteins and their genetic variants with SARS-CoV-2 proteins. | STAR Protoc | 2022 | 36052345 | PubTator, text mining | PubMed |
| A previously uncharacterized O-glycopeptidase from Akkermansia muciniphila requires the Tn-antigen for cleavage of the peptide bond. | J Biol Chem | 2022 | 36049519 | PubTator, text mining | PubMed |
| Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series. | Front Allergy | 2022 | 36032509 | PubTator, text mining | PubMed |
| The role of the complement system in Multiple Sclerosis: A review. | Front Immunol | 2022 | 36032156 | PubTator, text mining | PubMed |
| Targeting thromboinflammation in COVID-19 - A narrative review of the potential of C1 inhibitor to prevent disease progression. | Mol Immunol | 2022 | 36030710 | PubTator, text mining | PubMed |
| Coagulation and complement: Key innate defense participants in a seamless web. | Front Immunol | 2022 | 36016942 | PubTator, text mining | PubMed |
| Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus. | Vaccines (Basel) | 2022 | 36016108 | PubTator, text mining | PubMed |
| The Exploration of Complement-Resistance Mechanisms of Pathogenic Gram-Negative Bacteria to Support the Development of Novel Therapeutics. | Pathogens | 2022 | 36015050 | PubTator, text mining | PubMed |
| Autoantibodies against Complement Classical Pathway Components C1q, C1r, C1s and C1-Inh in Patients with Lupus Nephritis. | Int J Mol Sci | 2022 | 36012546 | PubTator, text mining | PubMed |
| Comparative Proteomic Assessment of Normal vs. Polyhydramnios Amniotic Fluid Based on Computational Analysis. | Biomedicines | 2022 | 36009368 | PubTator, text mining | PubMed |
| Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis. | Biomedicines | 2022 | 36009355 | PubTator, text mining | PubMed |
| Comprehensive identification of immuno-related transcriptional signature for active pulmonary tuberculosis by integrated analysis of array and single cell RNA-seq. | J Infect | 2022 | 36007657 | PubTator, text mining | PubMed |
| Minimal role for the alternative pathway in complement activation by HIT immune complexes. | J Thromb Haemost | 2022 | 35996342 | PubTator, text mining | PubMed |
| C1-inhibitor influence on platelet activation by thrombin receptors agonists. | Clin Appl Thromb Hemost | 2022 | 35996317 | PubTator, text mining | PubMed |
| Association of complement component 4 with neuroimmune abnormalities in the subventricular zone in schizophrenia and autism spectrum disorders. | Neurobiol Dis | 2022 | 35995342 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/710/papers?page=45